Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in pediatric and adolescent relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia
CTR20223262Phase 2Active
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Mar 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of inaticabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Juventas Cell Therapy Ltd.. Started Mar 2023; status: active.
02
Drugs
inaticabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20223262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223262.